Rivastigmine — Exelon — has two distinguishing features that shape its clinical use: it inhibits butyrylcholinesterase (BuChE) in addition to acetylcholinesterase (AChE), and it has a transdermal patch formulation that dramatically changes the side effect profile.
- Class
- Acetylcholinesterase + butyrylcholinesterase inhibitor
- Mechanism
- Inhibits both AChE and BuChE (dual inhibition may add benefit in advanced disease where BuChE activity rises)
- Typical dose
- Oral 1.5-6 mg BID; transdermal patch 4.6-13.3 mg/24h
- Half-life
- Oral ~1.5 hours; transdermal sustained release
- FDA indications
- Alzheimer's disease (mild-moderate), Parkinson's disease dementia
- Key adverse effects
- GI (oral form prominent — patch much less GI), application site reactions (patch), bradycardia
Transdermal patch is differentiator — significantly less GI burden than oral. FDA-approved for Parkinson's disease dementia (donepezil and galantamine off-label for this). Slower titration via patch.
The dual AChE/BuChE inhibition is theoretically more useful in advanced disease, where BuChE activity rises and may contribute to ongoing cholinergic deficit. Whether this translates into clinically meaningful superiority over donepezil is debated, but it provides a mechanistic rationale for considering rivastigmine in moderate-to-severe disease.
Rivastigmine inhibits two cholinesterase enzymes and has the strongest evidence in Lewy body and Parkinson's disease dementia — with a patch formulation that improves tolerability.
Mechanism note: Rivastigmine's niche is Lewy body and Parkinson's disease dementia — including hallucination control — and the patch formulation is what makes it tolerable.
The transdermal patch — Exelon Patch — is the practical differentiator. Oral rivastigmine has substantial GI burden; many patients can't tolerate the oral form. The patch bypasses GI absorption and produces dramatically less nausea, vomiting, and diarrhea. For the patient who couldn't tolerate oral AChEI side effects, the patch is often the answer. Strengths: 4.6, 9.5, and 13.3 mg per 24 hours, with site rotation required to avoid skin reactions.
Rivastigmine has the unique FDA approval for Parkinson's disease dementia — the only AChEI specifically labeled for this indication. Cholinergic deficit is part of the Parkinson's dementia picture, and rivastigmine has trial data supporting it. For the patient with established Parkinson's disease who develops cognitive impairment progressing to dementia, rivastigmine is the AChEI of choice.
Side effects are AChEI-class. Oral form has prominent GI; patch substantially reduces this. Skin reactions at patch sites are common (rotate sites every 14 days minimum, avoid same site repeated). Vivid dreams, bradycardia, syncope, muscle cramps continue to apply.
- Cost
- Oral generic ~$15-40/month. Patch generic ~$80-200/month (brand ~$400+).
- Generic status
- Oral and patch generic.
- Formulary typical
- Oral Tier 1-2. Patch Tier 2-3.
- Access friction
- Patch sometimes requires PA documenting oral GI intolerance.
Prescriber tip: For oral GI intolerance, patch PA usually approves on that rationale. Skin reactions are real — counsel site rotation explicitly.
For the patient with Alzheimer's disease who can't tolerate oral donepezil, rivastigmine patch is the next step. For Parkinson's disease dementia, rivastigmine is first-line.